Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.
Flawless balance sheet with solid track record.
Share Price & News
How has Vanda Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VNDA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VNDA underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: VNDA underperformed the US Market which returned 7.1% over the past year.
Price Volatility Vs. Market
How volatile is Vanda Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StRead This Before Buying Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares
1 month ago | Simply Wall StA Rising Share Price Has Us Looking Closely At Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) P/E Ratio
2 months ago | Simply Wall StDoes Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Pay Matter?
Is Vanda Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VNDA ($11.12) is trading above our estimate of fair value ($7.76)
Significantly Below Fair Value: VNDA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VNDA is good value based on its PE Ratio (5.1x) compared to the Biotechs industry average (18.3x).
PE vs Market: VNDA is good value based on its PE Ratio (5.1x) compared to the US market (15.6x).
Price to Earnings Growth Ratio
PEG Ratio: VNDA is good value based on its PEG Ratio (0.2x)
Price to Book Ratio
PB vs Industry: VNDA is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.7x).
How is Vanda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VNDA's forecast earnings growth (23.6% per year) is above the savings rate (2.2%).
Earnings vs Market: VNDA's earnings (23.6% per year) are forecast to grow faster than the US market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VNDA's revenue (8.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: VNDA's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VNDA's Return on Equity is forecast to be high in 3 years time
How has Vanda Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VNDA has a high level of non-cash earnings.
Growing Profit Margin: VNDA's current net profit margins (49.1%) are higher than last year (10.9%).
Past Earnings Growth Analysis
Earnings Trend: VNDA's earnings have grown significantly by 46.2% per year over the past 5 years.
Accelerating Growth: VNDA's earnings growth over the past year (439.9%) exceeds its 5-year average (46.2% per year).
Earnings vs Industry: VNDA earnings growth over the past year (439.9%) exceeded the Biotechs industry -4.5%.
Return on Equity
High ROE: VNDA's Return on Equity (28%) is considered high.
How is Vanda Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: VNDA's short term assets ($360.7M) exceed its short term liabilities ($59.2M).
Long Term Liabilities: VNDA's short term assets ($360.7M) exceed its long term liabilities ($12.9M).
Debt to Equity History and Analysis
Debt Level: VNDA is debt free.
Reducing Debt: VNDA has not had any debt for past 5 years.
Debt Coverage: VNDA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VNDA has no debt, therefore coverage of interest payments is not a concern.
What is Vanda Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VNDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VNDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VNDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VNDA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VNDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mihael Polymeropoulos (59yo)
Dr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer, President and Director since May, 2003. Dr. Polymeropoulos has also been the Chief F ...
CEO Compensation Analysis
Compensation vs Market: Mihael's total compensation ($USD4.28M) is above average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.
|Senior VP||1.75yrs||US$2.02m||0.015% $89.4k|
|Senior Vice President of Business Development||3.17yrs||US$2.01m||0.14% $828.1k|
|Acting CFO||0.17yr||no data||0.024% $147.8k|
|Chief Corporate Affairs & Communications Officer||0.75yr||no data||no data|
|Senior VP & Chief Marketing Officer||0.75yr||no data||no data|
|Chief People Officer||0.75yr||no data||no data|
|Head of Corporate Affairs||no data||no data||no data|
Experienced Management: VNDA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
|Independent Director||14.42yrs||US$234.99k||0.066% $397.7k|
|Independent Chairman of the Board||6.17yrs||US$249.33k||0.055% $333.6k|
|Independent Director||0.58yr||US$270.45k||no data|
|Independent Director||0.25yr||no data||0.00037% $2.2k|
|Independent Director||1.08yrs||US$545.62k||0.0092% $55.6k|
Experienced Board: VNDA's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VNDA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
Vanda Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Vanda Pharmaceuticals Inc.
- Ticker: VNDA
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$606.601m
- Shares outstanding: 54.55m
- Website: https://www.vandapharma.com
Number of Employees
- Vanda Pharmaceuticals Inc.
- 2200 Pennsylvania Avenue NW
- Suite 300E
- District Of Columbia
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VNDA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Apr 2006|
|VM4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2006|
|0LKB||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Apr 2006|
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 03:21|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.